These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24768766)

  • 1. Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects.
    Ramirez TA; Iyer RP; Ghasemi O; Lopez EF; Levin DB; Zhang J; Zamilpa R; Chou YM; Jin YF; Lindsey ML
    J Mol Cell Cardiol; 2014 Jul; 72():326-35. PubMed ID: 24768766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
    Higashikuni Y; Takaoka M; Iwata H; Tanaka K; Hirata Y; Nagai R; Sata M
    Hypertens Res; 2012 Jan; 35(1):62-9. PubMed ID: 21833001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure.
    Westermann D; Riad A; Lettau O; Roks A; Savvatis K; Becher PM; Escher F; Jan Danser AH; Schultheiss HP; Tschöpe C
    Hypertension; 2008 Dec; 52(6):1068-75. PubMed ID: 18955663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both.
    Miyazaki S; Kasai T; Miyauchi K; Miyazaki T; Akimoto Y; Takagi A; Aihara K; Kawamura M; Suwa S; Kojima S; Sumiyoshi M; Daida H
    Circ J; 2010 Jun; 74(6):1158-64. PubMed ID: 20378999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
    Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Tokutomi Y; Matsuba S; Nako H; Nakagata N; Kaneko T; Ogawa H; Kim-Mitsuyama S
    Hypertension; 2009 Sep; 54(3):633-8. PubMed ID: 19597038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct renin inhibition with aliskiren protects against myocardial ischemia/reperfusion injury by activating nitric oxide synthase signaling in spontaneously hypertensive rats.
    Zhang W; Han Y; Meng G; Bai W; Xie L; Lu H; Shao Y; Wei L; Pan S; Zhou S; Chen Q; Ferro A; Ji Y
    J Am Heart Assoc; 2014 Jan; 3(1):e000606. PubMed ID: 24473199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
    Koid SS; Ziogas J; Campbell DJ
    Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage overexpression of matrix metalloproteinase-9 in aged mice improves diastolic physiology and cardiac wound healing after myocardial infarction.
    Meschiari CA; Jung M; Iyer RP; Yabluchanskiy A; Toba H; Garrett MR; Lindsey ML
    Am J Physiol Heart Circ Physiol; 2018 Feb; 314(2):H224-H235. PubMed ID: 29030341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
    Crespo MJ; Cangiano JL; Altieri PI; Escobales N
    J Cardiovasc Pharmacol; 2012 Jun; 59(6):547-52. PubMed ID: 22370958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
    Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
    Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of renin-angiotensin-aldosterone system blockade on chlorhexidine gluconate-induced sclerosing encapsulated peritonitis in rats.
    Koçak G; Azak A; Astarcı HM; Huddam B; Karaca G; Ceri M; Can M; Sert M; Duranay M
    Ther Apher Dial; 2012 Feb; 16(1):75-80. PubMed ID: 22248199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPARC mediates early extracellular matrix remodeling following myocardial infarction.
    McCurdy SM; Dai Q; Zhang J; Zamilpa R; Ramirez TA; Dayah T; Nguyen N; Jin YF; Bradshaw AD; Lindsey ML
    Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H497-505. PubMed ID: 21602472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination angiotensin converting enzyme and direct renin inhibition in heart failure following experimental myocardial infarction.
    Connelly KA; Advani A; Advani S; Zhang Y; Thai K; Thomas S; Krum H; Kelly DJ; Gilbert RE
    Cardiovasc Ther; 2013 Apr; 31(2):84-91. PubMed ID: 21884026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
    Oparil S; Yarows SA; Patel S; Fang H; Zhang J; Satlin A
    Lancet; 2007 Jul; 370(9583):221-229. PubMed ID: 17658393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation.
    Kandalam V; Basu R; Abraham T; Wang X; Soloway PD; Jaworski DM; Oudit GY; Kassiri Z
    Circ Res; 2010 Mar; 106(4):796-808. PubMed ID: 20056917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone.
    Geiger H; Barranco E; Gorostidi M; Taylor A; Zhang X; Xiang Z; Zhang J
    J Clin Hypertens (Greenwich); 2009 Jun; 11(6):324-32. PubMed ID: 19527323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
    Imanishi T; Tsujioka H; Ikejima H; Kuroi A; Takarada S; Kitabata H; Tanimoto T; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    Hypertension; 2008 Sep; 52(3):563-72. PubMed ID: 18645051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of angiotensin II type 1 receptor antagonist valsartan on cardiac remodeling and left ventricular function in patients with acute ST-elevation myocardial infarction.
    Ovricenco E; Sinescu C; Dinescu S
    J Med Life; 2008; 1(3):323-33. PubMed ID: 20108509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.